CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 38 enrolled
Drug / intervention
Paroxetinedrug
Likely dose
Paroxetine (SSRI) - specific dose not statedAI-extracted
Key inclusion· 4
  • ✓Combat veterans ages 18+ with DSM-III-R PTSD diagnosis confirmed by CAPS
  • ✓PTSD illness duration minimum 6 months
  • ✓CGI-S score ≥4 and CAPS-2 severity score ≥50 at baseline
  • ✓Homozygous for S/S or L/L 5-HTT genotype
Key exclusion· 9
  • ✕Any other primary Axis I disorder (secondary depression to PTSD allowed)
  • ✕Suicidal ideation or suicide attempts in past 3 months
  • ✕Alcohol or substance abuse/dependence in past 6 months
  • ✕Clinically significant hepatic or renal disease

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00403455
NCT00403455Phase 3Completed
CompareCT.gov

Monoamine Transporters Genotypes: Risk of PTSD and Related Comorbidities

VA Office of Research and Development·interventional·Posted Nov 23, 2006·Updated Jul 2, 2018

In Brief

A Phase 3 clinical trial evaluating Paroxetine for PTSD. Completed, enrolled 38 participants across 1 site.

Detailed Summary

Dr. Wang's merit review is aimed at providing a better understanding of the relationship between SLC6A3/SLC6A4 and the mental health of veterans exposed to high levels of combat stress, specifically focusing on PTSD symptoms, related co-morbidities, treatment outcomes and seeks new approaches to therapy for our Veteran population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPTSD
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 23, 2006
Enrollment StartOct 1, 2006
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 19.6 years ago

Interventions

Paroxetinedrug

SSRI